Relmada Therapeutics IncNASDAQ:RLMD
- LAST PRICE2.9500
- TODAY'S CHANGE (%)-0.0900 (-2.9605%)
- Bid / Lots2.8000/ 2
- Ask / Lots3.2500/ 1
- Open / Previous Close3.0100 / 3.0400
- Day Range
- 52 Week Range
- Volume98,169
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RLMD |
|---|---|---|
| 09:32 ET | 426 | 3.01 |
| 09:38 ET | 221 | 3.02 |
| 10:14 ET | 1550 | 3.055 |
| 10:17 ET | 569 | 3.055 |
| 10:21 ET | 100 | 3.055 |
| 10:26 ET | 2416 | 3.07 |
| 10:42 ET | 2446 | 3.07 |
| 10:53 ET | 200 | 3.0539 |
| 11:09 ET | 100 | 3.075 |
| 11:11 ET | 100 | 3.08 |
| 11:13 ET | 1600 | 3.07 |
| 11:18 ET | 127 | 3.07 |
| 11:20 ET | 200 | 3.07 |
| 11:22 ET | 100 | 3.055 |
| 11:31 ET | 100 | 3.06 |
| 11:40 ET | 100 | 3.055 |
| 11:47 ET | 100 | 3.055 |
| 11:51 ET | 100 | 3.055 |
| 12:03 ET | 700 | 3.055 |
| 12:07 ET | 100 | 3.06 |
| 12:20 ET | 100 | 3.06 |
| 12:25 ET | 100 | 3.05 |
| 12:27 ET | 100 | 3.05 |
| 12:36 ET | 100 | 3.05 |
| 12:43 ET | 200 | 3.045 |
| 12:45 ET | 100 | 3.05 |
| 12:48 ET | 340 | 3.045 |
| 12:52 ET | 400 | 3.05 |
| 01:08 ET | 100 | 3.06 |
| 01:10 ET | 100 | 3.06 |
| 01:17 ET | 100 | 3.07 |
| 01:39 ET | 100 | 3.05 |
| 01:48 ET | 200 | 3.05 |
| 02:00 ET | 100 | 3.06 |
| 02:04 ET | 100 | 3.06 |
| 02:09 ET | 300 | 3.04 |
| 02:13 ET | 100 | 3.025 |
| 02:15 ET | 100 | 3.01 |
| 02:20 ET | 405 | 3.02 |
| 02:22 ET | 250 | 3.015 |
| 02:24 ET | 100 | 3 |
| 02:29 ET | 100 | 3 |
| 02:36 ET | 100 | 3.02 |
| 02:38 ET | 200 | 3.03 |
| 02:40 ET | 1200 | 3.0001 |
| 02:42 ET | 7240 | 3 |
| 02:49 ET | 2000 | 3 |
| 02:58 ET | 200 | 3 |
| 03:03 ET | 100 | 3.01 |
| 03:05 ET | 100 | 3 |
| 03:12 ET | 300 | 3 |
| 03:14 ET | 1700 | 3 |
| 03:16 ET | 1000 | 3.0042 |
| 03:18 ET | 3600 | 3.0001 |
| 03:20 ET | 9746 | 3 |
| 03:21 ET | 2090 | 3 |
| 03:23 ET | 100 | 3 |
| 03:27 ET | 100 | 3.005 |
| 03:32 ET | 124 | 3.005 |
| 03:34 ET | 1070 | 3 |
| 03:36 ET | 400 | 3 |
| 03:38 ET | 522 | 2.99 |
| 03:39 ET | 100 | 2.95 |
| 03:41 ET | 595 | 2.95 |
| 03:43 ET | 300 | 2.96 |
| 03:45 ET | 5777 | 2.94 |
| 03:48 ET | 1500 | 2.94 |
| 03:50 ET | 200 | 2.94 |
| 03:52 ET | 200 | 2.92 |
| 03:54 ET | 900 | 2.92 |
| 03:56 ET | 4711 | 2.94 |
| 03:57 ET | 300 | 2.97 |
| 03:59 ET | 1593 | 2.95 |
Today
Yesterday
Jun 6, 2024
Allegations Against Relmada Therapeutics, Inc.: Schall Law Firm Starts Investigation and Urges Impacted Investors to Reach Out, from 1:16PM ET on Thursday Jun 06, 2024 by Dow Jones
1:16PM ET on Thursday Jun 06, 2024 by Dow Jones
Jun 5, 2024
Relmada Therapeutics, Inc. Allegations: Schall Law Firm Initiates Inquiry and Invites Affected Investors to Connect, from 1:48PM ET on Wednesday Jun 05, 2024 by Dow Jones
1:48PM ET on Wednesday Jun 05, 2024 by Dow JonesDJ Relmada Therapeutics Cut to Sell From Neutral by Goldman Sachs, from 8:32AM ET on Wednesday Jun 05, 2024 by Dow Jones
8:32AM ET on Wednesday Jun 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Relmada Therapeutics Inc | 89.0M | -0.9x | --- |
Leap Therapeutics Inc | 89.7M | -0.9x | --- |
PMV Pharmaceuticals Inc | 88.0M | -1.3x | --- |
Vor Biopharma Inc | 90.1M | -0.7x | --- |
Allovir Inc | 87.9M | -0.5x | --- |
Connect Biopharma Holdings Ltd | 90.4M | -1.8x | --- |
Company Information
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Its esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications.
Contact Information
- Headquarters
- 2222 Ponce De Leon Blvd. 3Rd FloorCORAL GABLES, FL, United States 33134
- Phone
- 646-876-3459
- Fax
- ---
Executives
- Independent Chairman of the Board
- Charles Casamento
- Chief Executive Officer, Director
- Sergio Traversa
- Chief Financial Officer
- Maged Shenouda
- Chief Accounting, Compliance Officer
- Charles Ence
- Acting Chief Scientific Officer
- Paolo Manfredi
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $89.0M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 30.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.51 |
EPS | $-3.13 |
Book Value | $2.84 |
P/E Ratio | -0.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
